Hormone replacement therapy can be used for breast cancer subtypes that are positive for the estrogen receptor (ER) or progesterone receptor (PR), while targeted therapies using antibodies, like trastuzumab, is effective against breast cancers that over-express human epidermal growth factor receptor (HER2). Here, PGR is linked to breast carcinoma.